Key result
Forthcoming Cochrane Review evaluates stem cell therapy in non-ischaemic dilated cardiomyopathy.
Why the study?
The efficacy and safety of stem cell therapy in adults with non-ischaemic dilated cardiomyopathy have not been established.
Key points are not available for this paper at this time.
Population
Adults with non-ischaemic dilated cardiomyopathy
Comparison
Stem cell therapy versus control or standard care
Design
Protocol for a Cochrane Review (Intervention)
Answers are grounded in this paper and cite their sources.
Stem cell therapy in non-ischaemic dilated cardiomyopathy should not yet inform practice; forthcoming Cochrane review will synthesize efficacy and safety evidence.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy and safety of stem cell therapy (SCT) in adults with non‐ischaemic dilated cardiomyopathy (DCM).
No takes yet. Share an insight, caveat, or question.
Diaz-Navarro et al. (2019) studied this question. Stem cell therapy efficacy and safety in adults with non-ischaemic dilated cardiomyopathy will be evaluated in a forthcoming Cochrane Review.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: